Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal
Journal of Thrombosis and Thrombolysis · 2024
DOI: 10.1007/s11239-024-02969-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Meghan E Peterson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA. meghan.…. Hauptthemen laut MEDLINE: Warfarin, Blood Coagulation Factors, International Normalized Ratio. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Non-activated four-factor prothrombin complex concentrate (4 F-PCC) has emerged as the preferred reversal strategy for patients on warfarin with life-threatening bleeding. Current dosing recommendations for 4 F-PCC require pre-treatment international normalized ratio (INR) and bodyweight values, resulting in ordering and administration delays. Studies have shown that alternative dosing regimens are safe and efficacious. This retrospective, single-center, pre- and post-protocol analysis was conducted to assess the efficacy of a pharmacist driven modified fixed-dose 4 F-PCC regimen versus package insert weight- and INR-based dosing regimen for warfarin reversal. The primary outcome was achievement of INR less than two. Secondary outcomes included dose and cost of 4 F-PCC, a time analysis, incidence of concomitant vitamin K administration, and incidence of thrombosis within seven days of 4 F-PCC. There were 195 patients included in the analysis, with 74 in the pre-cohort and 121 in the post-cohort. Baseline characteristics were similar between cohorts with the most common indication for warfarin use being atrial fibrillation (48.6% versus 47.1%) and reversal being intracerebral hemorrhage (68.9% versus 43.0%). Achievement of the primary endpoint occurred in 92% versus 95% (p = 0.097) of patients. A statistically significant difference was seen between cohorts regarding median dose and cost of 4 F-PCC administered (p < 0.001). Eleven thromboembolic events occurred with three events in the pre-cohort and eight events in the post-cohort (p = 0.453). A fixed-dose of 1500IU of 4 F-PCC was effective in reversing INR to less than two in most patients regardless of reversal indication with minimal thrombotic risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA. meghan.peterson@vumc.org.
- Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, B-131 VUH, Nashville, TN, 37232, USA.
- Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Zitieren
APA
Peterson, M. E., Jaynes, M. P., Berardi, S., & Morton, C. (2024). Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-02969-0
Vancouver
Peterson ME, Jaynes MP, Berardi S, Morton C. Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-02969-0
BibTeX
@article{Peterson2024,
author = {Peterson, Meghan E and Jaynes, Megan P and Berardi, Sarah and Morton, Colleen},
title = {Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2024},
doi = {10.1007/s11239-024-02969-0}
}
EUVIMED